Important Notice for Altimmune Investors: Class Action Lawsuit Insights

Overview of the Altimmune Class Action Lawsuit

Investors associated with Altimmune, Inc. are urged to pay close attention to recent developments regarding a class action securities lawsuit announced by Levi & Korsinsky, LLP. This lawsuit is primarily aimed at gathering claims from investors who experienced losses due to alleged securities fraud during a specific timeframe. Interested parties must reach out to the firm before October 6, 2025, to discuss their legal rights and options for potential recovery.

Class Definition and Background

The lawsuit specifically seeks to represent investors affected by reported incidents of securities fraud that occurred between August 10, 2023, and June 25, 2025. During this period, significant events concerning the company’s financial disclosures and trial results, particularly regarding the investigation of Pemvidutide in the treatment of MASH, were brought to light.

As part of the class action, interested investors can find more information and submit their claims through an online submission form provided by Levi & Korsinsky. Investors can directly contact the law firm's dedicated attorney, Joseph E. Levi, via email or telephone for immediate assistance.

Case Details

A notable moment in this case occurred on June 26, 2025, when Altimmune published disturbing results related to its IMPACT Phase 2b MASH trial. The company's prior communications engendered optimistic expectations about the trial's outcomes; however, the actual results revealed that Altimmune failed to meet statistical significance in the primary endpoint, which concerned fibrosis reduction.

While the analysis indicated an optimistic trend towards fibrosis improvement, the results were undermined by an unexpectedly high response from the placebo group. This finding raised considerable concerns and was met with indifference by the company executives when queries were directed towards the unexpectedly negative outcomes. They attributed this lack of statistical significance to the Phase 2 nature of the trial and expressed hopes for improved results in future Phase 3 trials.

In response to this unfortunate reveal, Altimmune’s stock price experienced a steep decline, plummeting from $7.71 on June 25, 2025, to $3.61 the following day, marking a staggering 53.2% drop in just 24 hours. This drastic move in share price has prompted further investigation and led to the initiation of the class action lawsuit. The significant loss incurred by investors has galvanized the legal response from Levi & Korsinsky, who seek to rectify these wrongs through potential compensatory actions.

Next Steps for Investors

For affected investors of Altimmune during the aforementioned period, there remains a limited window to engage legally. They have until October 6, 2025, to file as a lead plaintiff if they wish to partake in the class action. There is no requirement to serve in this capacity to share in any possible recovery resulting from the lawsuit.

Importantly, participation in the lawsuit is structured so that it incurs no out-of-pocket costs for class members, allowing investors to claim compensation without immediate financial commitment. Levi & Korsinsky assures that their extensive track record with securities litigation further strengthens investors' positions in this proceeding.

Why Choose Levi & Korsinsky?

With over two decades of experience, the legal team at Levi & Korsinsky has gained a reputation for effectively advocating for shareholders, managing to recover millions of dollars for clients across various high-stakes cases. Their track record positions them as one of the leading securities litigation firms in the United States, consistently ranking within the top performers available.

Contact Information

Investors seeking further information or wishing to file claims can directly communicate with Levi & Korsinsky through mail, email, or phone. Joseph E. Levi and Ed Korsinsky are both ready to assist clients navigate this complex situation effectively. Information can be directed to:

Levi & Korsinsky, LLP
33 Whitehall Street, 17th Floor
New York, NY 10004
Tel: (212) 363-7500
Email: [email protected]
Website: www.zlk.com